Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
200 shown of 6,857 total abstracts
  1. Abstract 92142026-06-01 · 20:30 CT · S100A
    Quality of life outcomes with Imfinzi in patients with NSCLC
    A. Spira, T. Mok, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  2. Abstract 98082026-06-04 · 21:30 CT · Hall B1
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-146
    M. Reck, L. Paz-Ares · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 91132026-06-04 · 19:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-42 study)
    R. Herbst, S. Antonia · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 96572026-06-02 · 15:45 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-27 study)
    M.C. Garassino, A. Spira, J. Cortes, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 93732026-06-04 · 18:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-488
    R. Herbst, G. Curigliano, E. Winer, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 97052026-06-04 · 14:30 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-3
    C. Saura, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  7. Abstract 93302026-06-04 · 21:45 CT · S406
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Antonia, A. Spira, J. Brahmer · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 93722026-06-05 · 14:00 CT · S406
    FLAURA-174: Tagrisso (osimertinib) adjuvant in NSCLC
    C. Saura, G. Curigliano, S. Peters · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 97892026-06-05 · 14:30 CT · E450
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-781 study)
    M. Reck, J. Brahmer, S. Antonia · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 90242026-06-01 · 15:15 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-98 study)
    J. Cortes, R. Herbst · Royal Marsden Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  11. Abstract 91142026-06-05 · 15:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-771 study)
    H. Borghaei, S. Modi, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 98172026-06-01 · 18:00 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with NSCLC
    M.C. Garassino, A. Spira, J. Brahmer, et al. · MD Anderson Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract e120122026-06-04 · 19:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-126
    J. Cortes, G. Curigliano, A. Spira, et al. · Chinese University of Hong Kong
    Publication OnlyLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 98672026-06-01 · 20:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-728
    F. Andre, R. Herbst, H. Borghaei, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  15. Abstract 93802026-06-05 · 15:00 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    M.C. Garassino, S. Tolaney, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 91382026-06-02 · 16:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-485
    H. Rugo, J. Brahmer, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  17. Abstract 96202026-06-02 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-716 study)
    S. Antonia, N. Rizvi, S. Modi, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 92782026-06-04 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-820 study)
    M.C. Garassino, L. Paz-Ares, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  19. Abstract LBA4018LBA2026-06-05 · 14:15 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    P. Schmid, J. Brahmer, G. Curigliano, et al. · National Cancer Center Japan
    Late-Breaking Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  20. Abstract 91302026-06-03 · 13:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-273
    J. Cortes, M.C. Garassino · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  21. Abstract 96112026-06-03 · 20:30 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    A. Spira, E. Winer · MD Anderson Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  22. Abstract TPS80212026-06-04 · 19:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-541
    F. Andre, E. Winer, R. Herbst, et al. · Massachusetts General Hospital
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 99212026-06-03 · 14:00 CT · E450
    Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-290
    E. Winer, S. Modi, S. Tolaney, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  24. Abstract 92712026-06-03 · 21:15 CT · E450
    IMpower-254: Tecentriq (atezolizumab) 2L in NSCLC
    T. Mok, M.C. Garassino, S. Modi · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract e120242026-06-04 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-742 study)
    S. Modi, C. Saura · Royal Marsden Hospital
    Publication OnlyLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 95422026-06-03 · 20:00 CT · E450
    DESTINY-Breast-597: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    N. Rizvi, C. Robert, C. Saura, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 98032026-06-04 · 13:30 CT · Arie Crown Theater
    Quality of life outcomes with Tagrisso in patients with NSCLC
    M. Krop, M.C. Garassino · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  28. Abstract 90782026-06-01 · 20:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-23
    H. Rugo, S. Modi, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 92322026-06-05 · 15:30 CT · Hall B1
    Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-560
    T. Mok, F. Andre, R. Herbst · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 99912026-06-02 · 14:30 CT · Hall B1
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-510
    M.C. Garassino, M. Reck, J. Cortes, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 93912026-06-03 · 13:45 CT · E450
    IMpower-800: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    G. Curigliano, L. Paz-Ares, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract e120312026-06-01 · 14:45 CT · S100A
    PACIFIC-626: Imfinzi (durvalumab) 1L in SCLC
    J. Brahmer, R. Herbst · National Cancer Center Japan
    Publication OnlyLung Cancer—Small Cell📄🖼️
  33. Abstract 92752026-06-03 · 14:00 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-433
    F. Andre, H. Borghaei, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  34. Abstract 96232026-06-04 · 13:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-996 study)
    C. Saura, M. Reck, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  35. Abstract 93022026-06-01 · 21:00 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-393 study)
    S. Antonia, H. Borghaei, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  36. Abstract 99332026-06-05 · 14:15 CT · E450
    Long-term follow-up of Opdivo maintenance for NSCLC: CheckMate-929
    S. Peters, S. Tolaney, H. Rugo, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract LBA4036LBA2026-06-02 · 21:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-330
    C. Robert, S. Antonia, T. Mok, et al. · Chinese University of Hong Kong
    Late-Breaking Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  38. Abstract 93112026-06-04 · 14:00 CT · S100A
    Quality of life outcomes with Tecentriq in patients with NSCLC
    A. Spira, P. Schmid, J. Cortes, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  39. Abstract 91992026-06-01 · 14:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-512
    L. Paz-Ares, F. Andre, A. Spira · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 95422026-06-04 · 21:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-478 study)
    E. Winer, M. Reck, S. Tolaney · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  41. Abstract 99412026-06-03 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-394 study)
    P. Schmid, H. Rugo, H. Borghaei, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  42. Abstract 98972026-06-04 · 15:45 CT · S406
    CheckMate-750: Opdivo (nivolumab) 3L+ in NSCLC
    C. Robert, S. Peters · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 92382026-06-03 · 14:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-30
    F. Andre, T. Mok · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 96142026-06-03 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-736 study)
    S. Peters, L. Paz-Ares, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  45. Abstract 96012026-06-04 · 14:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-128
    N. Rizvi, E. Winer, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  46. Abstract 92282026-06-05 · 16:45 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    H. Borghaei, G. Curigliano · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  47. Abstract LBA4046LBA2026-06-01 · 13:15 CT · E450
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-494 study)
    S. Peters, A. Spira · Royal Marsden Hospital
    Plenary SessionLung Cancer—Small Cell📄🖼️
  48. Abstract LBA4047LBA2026-06-04 · 13:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-994
    F. Andre, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionLung Cancer—Small Cell📄🖼️
  49. Abstract 92012026-06-02 · 20:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-591
    N. Rizvi, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  50. Abstract 91062026-06-02 · 15:00 CT · Hall B1
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-984
    A. Spira, F. Andre, C. Saura, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  51. Abstract 97902026-06-03 · 14:45 CT · S406
    Quality of life outcomes with Keytruda in patients with NSCLC
    N. Rizvi, S. Antonia, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  52. Abstract 95112026-06-05 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-417 study)
    L. Paz-Ares, M. Krop · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  53. Abstract 93122026-06-05 · 19:45 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-126
    S. Modi, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  54. Abstract 98022026-06-03 · 19:45 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-366 study)
    S. Tolaney, J. Cortes, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Small Cell📄🖼️
  55. Abstract 92132026-06-01 · 18:15 CT · S100A
    PACIFIC-983: Imfinzi (durvalumab) 2L in NSCLC
    C. Saura, H. Borghaei, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  56. Abstract TPS80552026-06-03 · 20:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-685
    R. Herbst, G. Curigliano, N. Rizvi · Stanford Cancer Institute
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  57. Abstract 93572026-06-04 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for NSCLC: CheckMate-48
    S. Antonia, J. Cortes, A. Spira, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  58. Abstract 94322026-06-04 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-904 study)
    T. Mok, H. Rugo, H. Borghaei, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  59. Abstract TPS80582026-06-01 · 16:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-545 study)
    T. Mok, F. Andre, J. Brahmer, et al. · Royal Marsden Hospital
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract 95862026-06-02 · 16:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-732 study)
    S. Modi, H. Borghaei · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 92752026-06-02 · 18:30 CT · Hall B1
    KEYNOTE-706: Keytruda (pembrolizumab) maintenance in SCLC
    S. Antonia, C. Robert, E. Winer, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  62. Abstract 96672026-06-05 · 19:00 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-903
    M.C. Garassino, G. Curigliano, S. Modi · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  63. Abstract 99992026-06-05 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-891 study)
    T. Mok, F. Andre, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 95612026-06-01 · 13:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-681 study)
    M. Krop, G. Curigliano, M. Reck, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  65. Abstract 98442026-06-03 · 16:30 CT · S406
    IMpower-402: Tecentriq (atezolizumab) 3L+ in NSCLC
    G. Curigliano, H. Borghaei · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  66. Abstract 98912026-06-02 · 13:00 CT · E450
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-596 study)
    S. Peters, S. Tolaney · Stanford Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  67. Abstract 91632026-06-01 · 19:45 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    J. Cortes, M. Krop, P. Schmid, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  68. Abstract 92482026-06-02 · 18:15 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-865
    F. Andre, S. Peters · Massachusetts General Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  69. Abstract TPS80682026-06-03 · 16:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-244 study)
    R. Herbst, M. Krop, J. Cortes · Vall d'Hebron Institute of Oncology
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  70. Abstract 94812026-06-01 · 15:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-294 study)
    S. Peters, A. Spira, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  71. Abstract 95982026-06-02 · 18:45 CT · Hall B1
    IMpower-388: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    C. Robert, E. Winer · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  72. Abstract 90892026-06-04 · 21:15 CT · E450
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-842
    J. Brahmer, R. Herbst, C. Saura, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 94022026-06-04 · 13:00 CT · E450
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-124
    C. Saura, F. Andre, M. Reck, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  74. Abstract 98112026-06-03 · 14:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-66
    A. Spira, J. Brahmer, L. Paz-Ares · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  75. Abstract 94462026-06-05 · 19:15 CT · S406
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-551
    R. Herbst, S. Modi · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  76. Abstract 95002026-06-02 · 13:30 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-262
    G. Curigliano, M.C. Garassino, N. Rizvi · Karolinska Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  77. Abstract 91492026-06-01 · 16:30 CT · S406
    Long-term follow-up of Enhertu 3L+ for NSCLC: DESTINY-Breast-483
    J. Brahmer, G. Curigliano, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  78. Abstract 91902026-06-02 · 18:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with SCLC
    R. Herbst, S. Peters, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  79. Abstract 98292026-06-01 · 15:00 CT · Hall B1
    Long-term follow-up of Keytruda 1L for SCLC: KEYNOTE-975
    J. Cortes, S. Tolaney, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  80. Abstract 92802026-06-01 · 21:30 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    H. Rugo, S. Modi · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  81. Abstract 90802026-06-01 · 21:00 CT · Hall B1
    PACIFIC-612: Imfinzi (durvalumab) maintenance in SCLC
    S. Modi, J. Cortes · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  82. Abstract 92602026-06-05 · 13:00 CT · Arie Crown Theater
    KEYNOTE-821: Keytruda (pembrolizumab) adjuvant in SCLC
    H. Rugo, S. Modi · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  83. Abstract 98142026-06-04 · 18:00 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-922
    C. Saura, E. Winer, J. Cortes, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  84. Abstract 95802026-06-01 · 13:30 CT · S100A
    CheckMate-642: Opdivo (nivolumab) 2L in NSCLC
    A. Spira, F. Andre, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  85. Abstract 90932026-06-03 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-818 study)
    F. Andre, N. Rizvi, M. Krop, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 90272026-06-04 · 21:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-487
    M. Reck, S. Tolaney, R. Herbst, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  87. Abstract 90292026-06-04 · 13:15 CT · S406
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-413
    H. Rugo, F. Andre, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  88. Abstract 97202026-06-04 · 21:00 CT · S406
    FLAURA-754: Tagrisso (osimertinib) adjuvant in NSCLC
    G. Curigliano, A. Spira, T. Mok, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  89. Abstract 97662026-06-03 · 18:15 CT · E450
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-658
    R. Herbst, N. Rizvi, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 96282026-06-02 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-132
    J. Cortes, G. Curigliano, E. Winer, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  91. Abstract 91122026-06-05 · 18:00 CT · S100A
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-363
    G. Curigliano, A. Spira, E. Winer, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  92. Abstract TPS80912026-06-03 · 18:15 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with SCLC
    C. Robert, J. Cortes, F. Andre · Karolinska Institute
    Trials in Progress Poster SessionLung Cancer—Small Cell📄🖼️
  93. Abstract 93112026-06-01 · 18:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-529
    T. Mok, P. Schmid · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  94. Abstract 97532026-06-03 · 19:00 CT · E450
    FLAURA-187: Tagrisso (osimertinib) adjuvant in NSCLC
    S. Peters, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  95. Abstract 90392026-06-05 · 19:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-810
    T. Mok, S. Peters, M. Krop, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  96. Abstract 97192026-06-03 · 21:45 CT · E450
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-684
    L. Paz-Ares, S. Antonia, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  97. Abstract 96792026-06-02 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-370 study)
    M.C. Garassino, E. Winer, J. Brahmer, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  98. Abstract 97092026-06-01 · 20:45 CT · Hall B1
    KEYNOTE-201: Keytruda (pembrolizumab) neoadjuvant in SCLC
    S. Antonia, N. Rizvi, L. Paz-Ares · Karolinska Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  99. Abstract 94692026-06-04 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-719 study)
    R. Herbst, A. Spira, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 98432026-06-01 · 21:30 CT · Arie Crown Theater
    FLAURA-714: Tagrisso (osimertinib) 1L in NSCLC
    A. Spira, C. Saura, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  101. Abstract 90112026-06-04 · 21:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-759
    L. Paz-Ares, F. Andre, C. Robert · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  102. Abstract 96722026-06-03 · 18:00 CT · Arie Crown Theater
    FLAURA-126: Tagrisso (osimertinib) 1L in NSCLC
    J. Cortes, C. Robert, P. Schmid · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  103. Abstract 98742026-06-01 · 16:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-837 study)
    J. Cortes, S. Antonia · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  104. Abstract LBA4103LBA2026-06-03 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-288 study)
    L. Paz-Ares, E. Winer · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  105. Abstract 97932026-06-03 · 14:45 CT · S100A
    CheckMate-228: Opdivo (nivolumab) maintenance in NSCLC
    E. Winer, F. Andre · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 99812026-06-03 · 20:15 CT · Arie Crown Theater
    CheckMate-167: Opdivo (nivolumab) adjuvant in NSCLC
    C. Robert, G. Curigliano, J. Cortes, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  107. Abstract 90492026-06-05 · 16:30 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-528
    J. Brahmer, M. Reck · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  108. Abstract 91972026-06-02 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-759 study)
    L. Paz-Ares, C. Saura, G. Curigliano · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 94972026-06-02 · 16:15 CT · E450
    IMpower-387: Tecentriq (atezolizumab) 2L in NSCLC
    H. Rugo, H. Borghaei, M. Reck, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 97272026-06-04 · 20:00 CT · Hall B1
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-290
    M. Krop, S. Peters, F. Andre, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  111. Abstract 92842026-06-05 · 20:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-371 study)
    S. Tolaney, S. Modi · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  112. Abstract 98342026-06-05 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-22 study)
    A. Spira, T. Mok · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  113. Abstract 96502026-06-05 · 21:15 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-656
    C. Robert, R. Herbst, P. Schmid · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  114. Abstract LBA4113LBA2026-06-03 · 18:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-927
    S. Modi, C. Robert, S. Tolaney, et al. · Institut Gustave Roussy
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  115. Abstract 97832026-06-01 · 15:00 CT · Arie Crown Theater
    DESTINY-Breast-732: Enhertu (trastuzumab deruxtecan) adjuvant in NSCLC
    H. Borghaei, T. Mok · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 95682026-06-04 · 18:30 CT · S406
    FLAURA-61: Tagrisso (osimertinib) maintenance in NSCLC
    A. Spira, M. Krop · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  117. Abstract 92272026-06-01 · 14:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-167
    C. Saura, N. Rizvi, C. Robert, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  118. Abstract 95842026-06-04 · 18:15 CT · E450
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-245
    L. Paz-Ares, S. Antonia, A. Spira · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  119. Abstract 98682026-06-02 · 19:15 CT · S406
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-325
    M. Reck, M.C. Garassino, R. Herbst · Institut Gustave Roussy
    Poster SessionLung Cancer—Small Cell📄🖼️
  120. Abstract LBA4119LBA2026-06-01 · 15:15 CT · S100A
    PACIFIC-799: Imfinzi (durvalumab) 2L in SCLC
    S. Modi, S. Antonia, G. Curigliano, et al. · University of Chicago
    Late-Breaking Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  121. Abstract 93332026-06-05 · 15:15 CT · Hall B1
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-732
    F. Andre, S. Modi, C. Robert, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  122. Abstract 99342026-06-01 · 13:15 CT · Hall B1
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-425
    M.C. Garassino, H. Borghaei · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  123. Abstract 97692026-06-05 · 13:45 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with NSCLC
    L. Paz-Ares, C. Saura, T. Mok · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  124. Abstract 93492026-06-05 · 16:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-397 study)
    L. Paz-Ares, H. Rugo, P. Schmid, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  125. Abstract 94742026-06-01 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda maintenance for SCLC: KEYNOTE-346
    J. Brahmer, M. Krop, C. Saura, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  126. Abstract 97142026-06-05 · 20:30 CT · Hall B1
    FLAURA-132: Tagrisso (osimertinib) 1L in NSCLC
    T. Mok, S. Tolaney, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  127. Abstract LBA4126LBA2026-06-03 · 18:45 CT · Hall B1
    DESTINY-Breast-772: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    M. Krop, E. Winer, P. Schmid, et al. · Dana-Farber Cancer Institute
    Late-Breaking Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  128. Abstract 91102026-06-05 · 16:15 CT · E450
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-237
    S. Peters, P. Schmid, G. Curigliano · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  129. Abstract 98302026-06-03 · 19:30 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-350
    M. Reck, J. Brahmer, S. Peters, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  130. Abstract 96252026-06-05 · 14:15 CT · Hall B1
    PACIFIC-413: Imfinzi (durvalumab) 1L in SCLC
    G. Curigliano, M. Krop, J. Brahmer, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  131. Abstract 99412026-06-02 · 15:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-705
    E. Winer, G. Curigliano · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  132. Abstract 92922026-06-04 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-403 study)
    M. Krop, T. Mok, A. Spira, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  133. Abstract 94342026-06-04 · 16:15 CT · S100A
    Long-term follow-up of Keytruda maintenance for NSCLC: KEYNOTE-653
    A. Spira, J. Cortes, C. Robert, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  134. Abstract 97652026-06-02 · 14:30 CT · Arie Crown Theater
    KEYNOTE-951: Keytruda (pembrolizumab) adjuvant in NSCLC
    A. Spira, S. Antonia, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  135. Abstract 93162026-06-03 · 16:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-495 study)
    J. Cortes, S. Antonia · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  136. Abstract 90072026-06-05 · 19:15 CT · E450
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-27
    J. Brahmer, M. Krop, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  137. Abstract 96272026-06-05 · 15:15 CT · S100A
    PACIFIC-27: Imfinzi (durvalumab) adjuvant in SCLC
    M. Krop, M.C. Garassino, G. Curigliano · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  138. Abstract 91202026-06-02 · 16:00 CT · S100A
    KEYNOTE-829: Keytruda (pembrolizumab) 2L in NSCLC
    C. Robert, T. Mok, M. Reck, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  139. Abstract 93282026-06-01 · 21:30 CT · Hall B1
    Long-term follow-up of Keytruda 1L for NSCLC: KEYNOTE-866
    H. Borghaei, C. Robert, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  140. Abstract 92332026-06-05 · 20:30 CT · E450
    Long-term follow-up of Enhertu 3L+ for NSCLC: DESTINY-Breast-199
    C. Saura, P. Schmid, J. Cortes, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  141. Abstract 91352026-06-02 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-720 study)
    G. Curigliano, L. Paz-Ares, J. Brahmer, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  142. Abstract 93432026-06-05 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-589 study)
    T. Mok, R. Herbst, M. Krop, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  143. Abstract 94682026-06-03 · 21:30 CT · S406
    PACIFIC-986: Imfinzi (durvalumab) neoadjuvant in NSCLC
    C. Saura, N. Rizvi, E. Winer, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  144. Abstract 91092026-06-04 · 21:45 CT · S100A
    Long-term follow-up of Keytruda 3L+ for SCLC: KEYNOTE-284
    J. Cortes, C. Saura, S. Modi, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  145. Abstract 99172026-06-05 · 18:45 CT · Arie Crown Theater
    FLAURA-208: Tagrisso (osimertinib) neoadjuvant in NSCLC
    H. Rugo, M. Reck, J. Brahmer · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  146. Abstract 96152026-06-02 · 15:15 CT · E450
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-188 study)
    R. Herbst, T. Mok · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  147. Abstract 98692026-06-05 · 21:45 CT · S406
    Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-567
    J. Brahmer, H. Rugo · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  148. Abstract 91652026-06-05 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-376 study)
    C. Robert, T. Mok, G. Curigliano, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Small Cell📄🖼️
  149. Abstract 91042026-06-02 · 19:00 CT · S406
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-110 study)
    G. Curigliano, C. Saura, M. Krop · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  150. Abstract 99982026-06-01 · 13:45 CT · E450
    FLAURA-374: Tagrisso (osimertinib) 2L in NSCLC
    J. Cortes, M.C. Garassino, P. Schmid, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  151. Abstract 96132026-06-05 · 18:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-74
    M. Krop, J. Brahmer, S. Modi, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  152. Abstract TPS81512026-06-03 · 18:15 CT · E450
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-588
    J. Cortes, C. Saura · Karolinska Institute
    Trials in Progress Poster SessionLung Cancer—Small Cell📄🖼️
  153. Abstract 97702026-06-05 · 19:45 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-978
    M. Reck, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  154. Abstract 91672026-06-05 · 20:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-378
    S. Peters, M. Krop · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  155. Abstract 99482026-06-02 · 15:00 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-324 study)
    E. Winer, H. Borghaei, M. Krop, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  156. Abstract 91252026-06-02 · 14:45 CT · E450
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-703
    M. Reck, S. Antonia, C. Robert, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  157. Abstract 97162026-06-03 · 14:45 CT · Arie Crown Theater
    DESTINY-Breast-972: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    H. Borghaei, R. Herbst, M. Krop · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  158. Abstract 93692026-06-04 · 13:15 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for SCLC: KEYNOTE-400
    S. Tolaney, A. Spira, E. Winer, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  159. Abstract 96302026-06-04 · 20:30 CT · S406
    PACIFIC-186: Imfinzi (durvalumab) 3L+ in SCLC
    R. Herbst, P. Schmid, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  160. Abstract 92942026-06-05 · 19:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-206
    H. Borghaei, P. Schmid, C. Robert · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  161. Abstract 91022026-06-02 · 16:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-130
    A. Spira, S. Modi, S. Peters · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  162. Abstract 99192026-06-05 · 21:30 CT · S100A
    DESTINY-Breast-553: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    H. Rugo, C. Robert, M. Krop, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  163. Abstract 94782026-06-03 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-610 study)
    L. Paz-Ares, M.C. Garassino, N. Rizvi, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  164. Abstract 95472026-06-01 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-706 study)
    A. Spira, C. Robert, E. Winer · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  165. Abstract TPS81642026-06-01 · 14:00 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    F. Andre, S. Peters, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Trials in Progress Poster SessionLung Cancer—Small Cell📄🖼️
  166. Abstract TPS81652026-06-01 · 15:45 CT · Hall B1
    PACIFIC-445: Imfinzi (durvalumab) 3L+ in SCLC
    S. Antonia, M. Reck, E. Winer · Princess Margaret Cancer Centre
    Trials in Progress Poster SessionLung Cancer—Small Cell📄🖼️
  167. Abstract 96782026-06-04 · 21:45 CT · Hall B1
    FLAURA-839: Tagrisso (osimertinib) neoadjuvant in NSCLC
    P. Schmid, N. Rizvi, M.C. Garassino, et al. · National Cancer Center Japan
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  168. Abstract 98742026-06-05 · 13:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-345 study)
    C. Saura, M. Reck, R. Herbst · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  169. Abstract 94892026-06-01 · 20:00 CT · Hall B1
    FLAURA-900: Tagrisso (osimertinib) 3L+ in NSCLC
    J. Cortes, M. Krop, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  170. Abstract 92392026-06-05 · 13:30 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-290
    M.C. Garassino, R. Herbst, M. Krop, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  171. Abstract 97492026-06-04 · 19:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-330 study)
    R. Herbst, H. Borghaei · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  172. Abstract 94352026-06-03 · 19:15 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-670
    S. Tolaney, H. Rugo, H. Borghaei · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  173. Abstract 93712026-06-01 · 15:45 CT · S406
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-448
    L. Paz-Ares, J. Cortes, A. Spira · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  174. Abstract 99822026-06-04 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for SCLC: KEYNOTE-321
    N. Rizvi, C. Robert, M. Reck · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  175. Abstract LBA4174LBA2026-06-05 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-301 study)
    G. Curigliano, N. Rizvi, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  176. Abstract 93022026-06-03 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-33 study)
    G. Curigliano, R. Herbst, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  177. Abstract 91512026-06-03 · 20:15 CT · S100A
    PACIFIC-278: Imfinzi (durvalumab) 1L in NSCLC
    J. Brahmer, C. Saura · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  178. Abstract 94122026-06-03 · 18:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-13 study)
    C. Saura, C. Robert, T. Mok, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  179. Abstract 98632026-06-01 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu maintenance for NSCLC: DESTINY-Breast-70
    H. Borghaei, C. Robert · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  180. Abstract 91212026-06-04 · 13:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-94
    M.C. Garassino, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  181. Abstract 96322026-06-01 · 20:15 CT · S406
    CheckMate-293: Opdivo (nivolumab) maintenance in NSCLC
    M. Krop, S. Antonia, M.C. Garassino · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  182. Abstract 92512026-06-04 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-639 study)
    M. Krop, M. Reck, L. Paz-Ares, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  183. Abstract 90942026-06-05 · 19:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-992
    L. Paz-Ares, A. Spira, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  184. Abstract 98522026-06-02 · 13:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-804 study)
    C. Saura, S. Tolaney, H. Borghaei, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  185. Abstract 90992026-06-05 · 18:30 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-86
    S. Tolaney, E. Winer, N. Rizvi · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  186. Abstract 93682026-06-01 · 20:00 CT · Hall B1
    PACIFIC-126: Imfinzi (durvalumab) 1L in SCLC
    M.C. Garassino, S. Modi, T. Mok, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  187. Abstract 92332026-06-05 · 20:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-581
    M. Krop, F. Andre, S. Peters · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  188. Abstract 99772026-06-04 · 16:45 CT · S100A
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-251
    N. Rizvi, J. Brahmer, F. Andre · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  189. Abstract 91332026-06-02 · 20:30 CT · E450
    FLAURA-824: Tagrisso (osimertinib) maintenance in NSCLC
    M. Reck, P. Schmid · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  190. Abstract 92592026-06-05 · 18:45 CT · E450
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-387
    J. Cortes, G. Curigliano, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  191. Abstract e121902026-06-01 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-732 study)
    E. Winer, R. Herbst, H. Rugo, et al. · National Cancer Center Japan
    Publication OnlyLung Cancer—Non-Small Cell Metastatic📄🖼️
  192. Abstract 95792026-06-05 · 21:00 CT · S100A
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-946
    P. Schmid, S. Peters, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  193. Abstract 95422026-06-01 · 16:30 CT · Hall B1
    KEYNOTE-46: Keytruda (pembrolizumab) 1L in SCLC
    A. Spira, C. Saura, F. Andre, et al. · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  194. Abstract TPS81932026-06-04 · 21:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-206 study)
    S. Modi, R. Herbst, M.C. Garassino · Princess Margaret Cancer Centre
    Trials in Progress Poster SessionLung Cancer—Small Cell📄🖼️
  195. Abstract 96852026-06-04 · 15:15 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-675
    C. Robert, C. Saura, F. Andre, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  196. Abstract 97652026-06-03 · 20:45 CT · Hall B1
    Long-term follow-up of Keytruda 1L for SCLC: KEYNOTE-876
    M.C. Garassino, G. Curigliano, C. Saura, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  197. Abstract 91852026-06-03 · 21:15 CT · S100A
    Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-212
    A. Spira, S. Antonia, E. Winer · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  198. Abstract 95652026-06-01 · 19:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-349
    J. Brahmer, L. Paz-Ares · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  199. Abstract 92642026-06-05 · 13:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-693 study)
    M. Reck, A. Spira, C. Robert · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  200. Abstract 94802026-06-02 · 20:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-814
    H. Borghaei, E. Winer, C. Saura, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.